Equities

NANO MRNA Co Ltd

NANO MRNA Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)176.00
  • Today's Change-1.00 / -0.56%
  • Shares traded120.70k
  • 1 Year change-18.52%
  • Beta1.0357
Data delayed at least 20 minutes, as of Apr 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.

  • Revenue in JPY (TTM)164.39m
  • Net income in JPY-1.05bn
  • Incorporated1996
  • Employees17.00
  • Location
    NANO MRNA Co LtdOhnoya Kyobashi Bldg., 1-4-10, KyobashiMINATO-KU 105-6226JapanJPN
  • Phone+81 364324791
  • Fax+81 364324794
  • Websitehttps://www.nanomrna.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3-D Matrix Ltd3.74bn-1.06bn9.36bn108.00--15.24--2.50-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
TMS Co Ltd0.00-960.04m9.55bn14.00--2.76-----25.89-25.890.0085.770.00-------26.14---26.78-----------------------11.51------
Linical Co Ltd12.52bn680.40m10.09bn759.0013.541.188.490.806330.1230.12554.28346.380.7251--3.9916,494,230.003.944.716.557.2333.1031.605.435.98--17,809.030.279345.368.326.5527.06-4.97-33.014.94
Veritas In Silico Inc360.36m33.05m10.61bn15.00311.756.54176.8029.435.245.2457.19250.05------24,023,730.00------------9.17--20.19--0.00--101.54--123.38------
AnGes Inc152.99m-7.44bn10.67bn145.00--0.3726--69.72-39.40-39.400.8083131.520.00450.10378.401,055,069.00-21.97-28.50-25.69-33.1412.7139.42-4,861.66-6,726.821.75--0.0137--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED18.49bn62.58m10.95bn387.00174.610.50343.720.592112.7912.793,779.784,437.990.45991.304.5147,770,930.000.15573.760.2064.6824.9124.120.33856.660.53561.770.308935.807.550.4997-26.56-33.8215.6820.11
Medinet Co Ltd724.63m-1.41bn11.53bn98.00--1.97--15.91-6.31-6.313.2322.880.122411.933.617,394,143.00-23.74-21.05-24.75-22.4717.7228.75-193.90-135.4019.58--0.00--4.40-7.90-14.66---17.67--
Kohjin Bio Co Ltd-100.00bn-100.00bn11.89bn157.00--3.73----------634.95------------------------1.15--0.4102--20.16--41.20------
ReproCell Inc2.51bn-217.49m12.11bn92.00--1.50--4.83-2.56-2.5629.4890.900.30084.867.4427,247,390.00-2.61-9.37-2.80-10.1143.5538.78-8.68-38.1211.94--0.00--32.1626.1046.91--28.24--
Nano Mrna Co Ltd164.39m-1.05bn12.46bn17.00--3.58--75.79-14.94-14.942.3449.400.029518.962.609,669,765.00-18.85-25.13-23.29-26.0480.6784.69-638.22-538.318.95--0.2418---23.42-4.8430.33------
RaQualia Pharma Inc1.90bn-323.66m13.06bn67.00--2.13--6.87-14.99-14.9987.98283.050.28963.133.1528,376,150.00-4.932.13-5.292.2687.1188.49-17.025.3212.35--0.05670.00-34.8520.62-144.74--0.0967--
Healios KK121.00m-3.82bn13.34bn64.00--2.86--110.24-55.07-55.071.7851.710.008--0.39291,890,625.00-25.27-23.55-35.99-28.5283.47---3,152.89-6,580.16---13.680.6756--34.44--26.04---22.00--
Ohki Healthcare Holdings Co Ltd327.51bn2.35bn14.28bn576.005.960.53025.380.0436170.32170.3223,747.191,914.312.3711.644.27568,593,700.001.651.957.989.115.207.120.69620.75390.8536--0.1913.289.454.91124.49-1.16-1.279.46
Oncolys Biopharma Inc63.04m-1.94bn14.38bn34.00--9.13--228.11-108.23-108.233.5475.100.02692.190.30011,854,059.00-82.64-45.75-97.13-51.8648.5560.46-3,075.14-233.665.15--0.1761---93.54-17.86-68.72--28.18--
Microwave Chemical Co Ltd1.89bn98.88m15.46bn59.00222.439.0687.818.174.454.45116.78109.320.65269.376.5332,055,120.003.41--4.65--54.51--5.23--2.6511.240.2309--41.24--168.39------
Data as of Apr 26 2024. Currency figures normalised to NANO MRNA Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.36%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 04 Apr 2024638.30k0.91%
Simplex Asset Management Co., Ltd.as of 04 Apr 2024321.10k0.46%
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.